Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
Published on: February 2, 2024
MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while
Meiou Liu1, Yasushi Akahori1, Naoko Imai1
1Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
Background:
The development of chimeric antigen receptor (CAR)-T cell therapies for solid tumors has attracted considerable attention, yet their clinical efficacy remains limited. Therefore, various efforts have been made to improve the efficacy of CAR-T cell therapy. As one promising strategy, incorporating the T-cell receptor (TCR) machinery into CAR structures has been reported to improve the efficacy of CAR-T cells in studies using conventional CARs targeting such as EGFR. However, in the case of peptide/major histocompatibility complex (pMHC)-targeted CARs, the advantages of exploiting TCR machinery have not been fully elucidated. We recently developed MAGE-A4-derived pMHC (MAGE-A4 pMHC)-targeted CAR-T cells (MA-CAR-T cells) using a highly specific human scFv antibody against MAGE-A4p230-239/HLA-A*02:01. We aimed to determine whether MAGE-A4 pMHC-targeted CAR-T cells using the TCR machinery (Hybrid MA-TCR-T cells) exhibit superior functionality without compromising antigen specificity.
Methods:
We constructed a retroviral vector expressing Hybrid MA-TCR where MAGE-A4 pMHC-specific scFv are fused to human TCR constant chains.
Results:
Hybrid MA-TCR-T cells demonstrated superior in vitro functions compared with MA-CAR-T cells, while maintaining strict antigen specificity. In addition, functional superiority of Hybrid MA-TCR-T cells to MA-CAR-T cells became more pronounced on repetitive antigen stimulation. In particular, Hybrid MA-TCR-T cells significantly inhibited tumor growth in an immunodeficient mouse model more effectively than MA-CAR-T cells. Ex vivo analyses indicated that their enhanced therapeutic efficacy might result from higher infiltration of functionally active, less differentiated Hybrid MA-TCR-T cells in tumor tissues.
Conclusions:
These findings suggest that leveraging the TCR machinery is a promising strategy for enhancing pMHC-targeted CAR-T cell therapy for solid tumors, potentially leading to more effective treatments.
Insights
Incorporating T-cell receptor (TCR) machinery into chimeric antigen receptor (CAR)-T cells enhances their effectiveness against solid tumors. This hybrid approach, demonstrated with MAGE-A4 pMHC-targeted cells, shows improved tumor inhibition and T-cell function.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise for solid tumors but faces efficacy limitations.
- Strategies to enhance CAR-T cell therapy include integrating T-cell receptor (TCR) machinery.
- The benefits of TCR machinery in peptide/major histocompatibility complex (pMHC)-targeted CARs are not fully understood.
Purpose of the Study:
- To investigate if MAGE-A4 pMHC-targeted CAR-T cells incorporating TCR machinery (Hybrid MA-TCR-T cells) offer superior functionality.
- To assess if Hybrid MA-TCR-T cells maintain strict antigen specificity compared to conventional MA-CAR-T cells.
- To evaluate the therapeutic potential of Hybrid MA-TCR-T cells in solid tumor treatment.
Main Methods:
- Constructed a retroviral vector for Hybrid MA-TCR expression, fusing MAGE-A4 pMHC-specific single-chain variable fragments (scFv) to human TCR constant chains.
- Compared in vitro and in vivo functions of Hybrid MA-TCR-T cells against MA-CAR-T cells.
- Performed ex vivo analyses to understand the mechanisms behind enhanced therapeutic efficacy.
Main Results:
- Hybrid MA-TCR-T cells exhibited enhanced in vitro functions and maintained strict antigen specificity compared to MA-CAR-T cells.
- The functional superiority of Hybrid MA-TCR-T cells was more evident upon repetitive antigen stimulation.
- Hybrid MA-TCR-T cells significantly inhibited tumor growth in a mouse model, attributed to increased infiltration of active, less differentiated T cells in tumor tissues.
Conclusions:
- Leveraging TCR machinery is a promising strategy for improving pMHC-targeted CAR-T cell therapy for solid tumors.
- Hybrid MA-TCR-T cells demonstrate enhanced therapeutic potential, suggesting a viable approach for more effective cancer treatments.
- Further research into TCR-enhanced CAR-T cells could lead to significant advancements in solid tumor immunotherapy.
